Copyright
©The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Radiol. Jan 28, 2026; 18(1): 116084
Published online Jan 28, 2026. doi: 10.4329/wjr.v18.i1.116084
Published online Jan 28, 2026. doi: 10.4329/wjr.v18.i1.116084
Radiotherapy combined with bevacizumab in gastrointestinal cancers: Balancing efficacy against the risk of intestinal perforation
Yan Xu, Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital of Army Medical University, Chongqing 400037, China
Xiao-Bing Huang, Yong-Gang He, Department of Hepatobiliary Medicine, The Second Affiliated Hospital of Army Medical University, Chongqing 400037, China
Co-corresponding authors: Xiao-Bing Huang and Yong-Gang He.
Author contributions: Xu Y drafted and edited the manuscript; Huang XB and He YG contributed to the conceptualization of the study and the critical review of the manuscript for important intellectual content, and they contributed equally to this articl as the co-corresponding authors of this manuscript; and all authors have read and approved the final version of the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yong-Gang He, Associate Chief Physician, Department of Hepatobiliary Medicine, The Second Affiliated Hospital of Army Medical University, No. 83 Xinqiaozheng Street, Chongqing 400037, China. xqyyhyg@tmmu.edu.cn
Received: November 2, 2025
Revised: November 15, 2025
Accepted: December 19, 2025
Published online: January 28, 2026
Processing time: 85 Days and 16.2 Hours
Revised: November 15, 2025
Accepted: December 19, 2025
Published online: January 28, 2026
Processing time: 85 Days and 16.2 Hours
Core Tip
Core Tip: The combination of radiotherapy and bevacizumab in gastrointestinal cancers offers enhanced efficacy but requires careful management due to an increased risk of intestinal perforation. Strategic patient selection and advanced radiotherapy techniques are essential to balance benefits and risks.